First-Line Nivolumab Plus Ipilimumab in Inoperable Epithelioid Malignant Pleural Mesothelioma: Real-World Experience From an Indian Tertiary Care Center
Cureus · 24.07.2026
DOI: 10.7759/cureus.113313 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cureus, erschienen am 24.07.2026. Verfasst von Avi Shah und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Geetanjali Medical College, Udaipur, IND. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical Oncology, Geetanjali Medical College, Udaipur, IND.
- General Medicine, Smt. Nathiba Hargovandas Lakhmichand (NHL) Municipal Medical College, Ahmedabad, IND.
- Surgical Oncology, Geetanjali Medical College, Udaipur, IND.
Zitieren
APA
Shah, A., Agarwal, A., Rajpuria, V., Ghodasara, S., Swami, J., Kanth, V., Dangar, H., & Jakhetiya, A. (2026). First-Line Nivolumab Plus Ipilimumab in Inoperable Epithelioid Malignant Pleural Mesothelioma: Real-World Experience From an Indian Tertiary Care Center. Cureus. https://doi.org/10.7759/cureus.113313
Vancouver
Shah A, Agarwal A, Rajpuria V, Ghodasara S, Swami J, Kanth V, et al. First-Line Nivolumab Plus Ipilimumab in Inoperable Epithelioid Malignant Pleural Mesothelioma: Real-World Experience From an Indian Tertiary Care Center. Cureus. 2026. doi:10.7759/cureus.113313
BibTeX
@article{Shah2026,
author = {Shah, Avi and Agarwal, Ankit and Rajpuria, Vishva and Ghodasara, Shiv and Swami, Jagdish and Kanth, Vibhav and Dangar, Hiren and Jakhetiya, Ashish},
title = {First-Line Nivolumab Plus Ipilimumab in Inoperable Epithelioid Malignant Pleural Mesothelioma: Real-World Experience From an Indian Tertiary Care Center},
journal = {Cureus},
year = {2026},
doi = {10.7759/cureus.113313}
}
EUVIMED